Novel Findings from CNVs Implicate Inhibitory and Excitatory Signaling Complexes in Schizophrenia

Neuron

Volumn 86, Issue 5, 2015, Pages 1203-1214

  Pocklington, Andrew J ^a   Rees, Elliott ^a   Walters, James T R ^a   Han, Jun ^a   Kavanagh, David H ^a,d   Chambert, Kimberly D ^b   Holmans, Peter ^a   Moran, Jennifer L ^b   McCarroll, Steven A ^b,c   Kirov, George ^a   O'Donovan, Michael C ^a   Owen, Michael J ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR;

ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; DISEASE ASSOCIATION; EXCITATORY POSTSYNAPTIC POTENTIAL; GABAERGIC TRANSMISSION; GENE DELETION; GENE DUPLICATION; GENE FREQUENCY; GENE LOCUS; GENE MUTATION; GENE REPLICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GLUTAMATERGIC SYNAPSE; HUMAN; INHIBITORY POSTSYNAPTIC POTENTIAL; MAJOR CLINICAL STUDY; NERVE CELL PLASTICITY; NEUROTRANSMISSION; PATHOGENESIS; PRIORITY JOURNAL; SCHIZOPHRENIA; ANIMAL; CASE CONTROL STUDY; GENETICS; MOUSE; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CASE-CONTROL STUDIES; DNA COPY NUMBER VARIATIONS; EXCITATORY POSTSYNAPTIC POTENTIALS; HUMANS; INHIBITORY POSTSYNAPTIC POTENTIALS; MICE; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

EID: 84930520305     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2015.04.022     Document Type: Article

References (65)

1. Ashburner M., Ball C.A., Blake J.A., Botstein D., Butler H., Cherry J.M., Davis A.P., Dolinski K., Dwight S.S., Eppig J.T., et al. Gene ontology: tool for the unification of biology. Nat. Genet. 2000, 25:25-29. The Gene Ontology Consortium.
2. Bartos M., Vida I., Jonas P. Synaptic mechanisms of synchronized gamma oscillations in inhibitory interneuron networks. Nat. Rev. Neurosci. 2007, 8:45-56.
3. Battaglia A., Hoyme H.E., Dallapiccola B., Zackai E., Hudgins L., McDonald-McGinn D., Bahi-Buisson N., Romano C., Williams C.A., Brailey L.L., et al. Further delineation of deletion 1p36 syndrome in 60 patients: a recognizable phenotype and common cause of developmental delay and mental retardation. Pediatrics 2008, 121:404-410.
4. Bauer E.P., Schafe G.E., LeDoux J.E. NMDA receptors and L-type voltage-gated calcium channels contribute to long-term potentiation and different components of fear memory formation in the lateral amygdala. J. Neurosci. 2002, 22:5239-5249.
5. Blake J.A., Bult C.J., Eppig J.T., Kadin J.A., Richardson J.E. The Mouse Genome Database: integration of and access to knowledge about the laboratory mouse. Nucleic Acids Res. 2014, 42:D810-D817. Mouse Genome Database Group.
6. Buzsáki G., Draguhn A. Neuronal oscillations in cortical networks. Science 2004, 304:1926-1929.
7. Buzsáki G., Watson B.O. Brain rhythms and neural syntax: implications for efficient coding of cognitive content and neuropsychiatric disease. Dialogues Clin. Neurosci. 2012, 14:345-367.
8. Carcea I., Froemke R.C. Cortical plasticity, excitatory-inhibitory balance, and sensory perception. Prog. Brain Res. 2013, 207:65-90.
9. Cardno A.G., Gottesman I.I. Twin studies of schizophrenia: from bow-and-arrow concordances to star wars Mx and functional genomics. Am. J. Med. Genet. 2000, 97:12-17.
10. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988, 1:179-186.
11. Darnell J.C., Van Driesche S.J., Zhang C., Hung K.Y., Mele A., Fraser C.E., Stone E.F., Chen C., Fak J.J., Chi S.W., et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 2011, 146:247-261.
12. Fernández E., Collins M.O., Uren R.T., Kopanitsa M.V., Komiyama N.H., Croning M.D., Zografos L., Armstrong J.D., Choudhary J.S., Grant S.G. Targeted tandem affinity purification of PSD-95 recovers core postsynaptic complexes and schizophrenia susceptibility proteins. Mol. Syst. Biol. 2009, 5:269.
13. Friston K.J. The disconnection hypothesis. Schizophr. Res. 1998, 30:115-125.
14. Fritschy J.M., Panzanelli P. GABAA receptors and plasticity of inhibitory neurotransmission in the central nervous system. Eur. J. Neurosci. 2014, 39:1845-1865.
15. Fromer M., Pocklington A.J., Kavanagh D.H., Williams H.J., Dwyer S., Gormley P., Georgieva L., Rees E., Palta P., Ruderfer D.M., et al. De novo mutations in schizophrenia implicate synaptic networks. Nature 2014, 506:179-184.
16. Girard S.L., Gauthier J., Noreau A., Xiong L., Zhou S., Jouan L., Dionne-Laporte A., Spiegelman D., Henrion E., Diallo O., et al. Increased exonic de novo mutation rate in individuals with schizophrenia. Nat. Genet. 2011, 43:860-863.
17. Girirajan S., Rosenfeld J.A., Coe B.P., Parikh S., Friedman N., Goldstein A., Filipink R.A., McConnell J.S., Angle B., Meschino W.S., et al. Phenotypic heterogeneity of genomic disorders and rare copy-number variants. N. Engl. J. Med. 2012, 367:1321-1331.
18. Glessner J.T., Reilly M.P., Kim C.E., Takahashi N., Albano A., Hou C., Bradfield J.P., Zhang H., Sleiman P.M., Flory J.H., et al. Strong synaptic transmission impact by copy number variations in schizophrenia. Proc. Natl. Acad. Sci. USA 2010, 107:10584-10589.
19. Glykys J., Mann E.O., Mody I. Which GABA(A) receptor subunits are necessary for tonic inhibition in the hippocampus?. J. Neurosci. 2008, 28:1421-1426.
20. Gulsuner S., Walsh T., Watts A.C., Lee M.K., Thornton A.M., Casadei S., Rippey C., Shahin H., Nimgaonkar V.L., Go R.C., et al. Spatial and temporal mapping of de novo mutations in schizophrenia to a fetal prefrontal cortical network. Cell 2013, 154:518-529. Consortium on the Genetics of Schizophrenia (COGS), PAARTNERS Study GroupPAARTNERS Study Group.
21. Heller E.A., Zhang W., Selimi F., Earnheart J.C., Ślimak M.A., Santos-Torres J., Ibañez-Tallon I., Aoki C., Chait B.T., Heintz N. The biochemical anatomy of cortical inhibitory synapses. PLoS ONE 2012, 7:e39572.
22. Husi H., Grant S.G. Isolation of 2000-kDa complexes of N-methyl-D-aspartate receptor and postsynaptic density 95 from mouse brain. J. Neurochem. 2001, 77:281-291.
23. Husi H., Ward M.A., Choudhary J.S., Blackstock W.P., Grant S.G. Proteomic analysis of NMDA receptor-adhesion protein signaling complexes. Nat. Neurosci. 2000, 3:661-669.
24. Inan M., Petros T.J., Anderson S.A. Losing your inhibition: linking cortical GABAergic interneurons to schizophrenia. Neurobiol. Dis. 2013, 53:36-48.
25. Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature 2008, 455:237-241. International Schizophrenia Consortium.
26. Iossifov I., Ronemus M., Levy D., Wang Z., Hakker I., Rosenbaum J., Yamrom B., Lee Y.H., Narzisi G., Leotta A., et al. De novo gene disruptions in children on the autistic spectrum. Neuron 2012, 74:285-299.
27. Joshi S., Kapur J. N-methyl-D-aspartic acid receptor activation downregulates expression of δ subunit-containing GABAA receptors in cultured hippocampal neurons. Mol. Pharmacol. 2013, 84:1-11.
28. Kehrer C., Maziashvili N., Dugladze T., Gloveli T. Altered excitatory-inhibitory balance in the NMDA-hypofunction model of schizophrenia. Front. Mol. Neurosci. 2008, 1:6.
29. Kirov G., Gumus D., Chen W., Norton N., Georgieva L., Sari M., O'Donovan M.C., Erdogan F., Owen M.J., Ropers H.H., Ullmann R. Comparative genome hybridization suggests a role for NRXN1 and APBA2 in schizophrenia. Hum. Mol. Genet. 2008, 17:458-465.
30. Kirov G., Pocklington A.J., Holmans P., Ivanov D., Ikeda M., Ruderfer D., Moran J., Chambert K., Toncheva D., Georgieva L., et al. De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Mol. Psychiatry 2012, 17:142-153.
31. Korn J.M., Kuruvilla F.G., McCarroll S.A., Wysoker A., Nemesh J., Cawley S., Hubbell E., Veitch J., Collins P.J., Darvishi K., et al. Integrated genotype calling and association analysis of SNPs, common copy number polymorphisms and rare CNVs. Nat. Genet. 2008, 40:1253-1260.
32. Laruelle M., Frankle W.G., Narendran R., Kegeles L.S., Abi-Dargham A. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation. Clin. Ther. 2005, 27:S16-S24.
33. Levinson D.F., Duan J., Oh S., Wang K., Sanders A.R., Shi J., Zhang N., Mowry B.J., Olincy A., Amin F., et al. Copy number variants in schizophrenia: confirmation of five previous findings and new evidence for 3q29 microdeletions and VIPR2 duplications. Am. J. Psychiatry 2011, 168:302-316.
34. Lewis D.A., Gonzalez-Burgos G. Pathophysiologically based treatment interventions in schizophrenia. Nat. Med. 2006, 12:1016-1022.
35. Lewis D.A., Curley A.A., Glausier J.R., Volk D.W. Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci. 2012, 35:57-67.
36. Malhotra D., Sebat J. CNVs: harbingers of a rare variant revolution in psychiatric genetics. Cell 2012, 148:1223-1241.
37. Malhotra D., McCarthy S., Michaelson J.J., Vacic V., Burdick K.E., Yoon S., Cichon S., Corvin A., Gary S., Gershon E.S., et al. High frequencies of de novo CNVs in bipolar disorder and schizophrenia. Neuron 2011, 72:951-963.
38. Mann E.O., Mody I. Control of hippocampal gamma oscillation frequency by tonic inhibition and excitation of interneurons. Nat. Neurosci. 2010, 13:205-212.
39. Martin L.J., Zurek A.A., MacDonald J.F., Roder J.C., Jackson M.F., Orser B.A. Alpha5GABAA receptor activity sets the threshold for long-term potentiation and constrains hippocampus-dependent memory. J. Neurosci. 2010, 30:5269-5282.
40. Miller R. Schizophrenic psychology, associative learning and the role of forebrain dopamine. Med. Hypotheses 1976, 2:203-211.
41. Myles-Worsley M., Tiobech J., Browning S.R., Korn J., Goodman S., Gentile K., Melhem N., Byerley W., Faraone S.V., Middleton F.A. Deletion at the SLC1A1 glutamate transporter gene co-segregates with schizophrenia and bipolar schizoaffective disorder in a 5-generation family. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 2013, 162B:87-95.
42. O'Roak B.J., Vives L., Girirajan S., Karakoc E., Krumm N., Coe B.P., Levy R., Ko A., Lee C., Smith J.D., et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature 2012, 485:246-250.
43. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 1995, 52:998-1007.
44. Pocklington A.J., Cumiskey M., Armstrong J.D., Grant S.G. The proteomes of neurotransmitter receptor complexes form modular networks with distributed functionality underlying plasticity and behaviour. Mol. Syst. Biol. 2006, 2. 10.1038/msb4100041.
45. Purcell S.M., Moran J.L., Fromer M., Ruderfer D., Solovieff N., Roussos P., O'Dushlaine C., Chambert K., Bergen S.E., Kähler A., et al. A polygenic burden of rare disruptive mutations in schizophrenia. Nature 2014, 506:185-190.
46. Rauch A., Wieczorek D., Graf E., Wieland T., Endele S., Schwarzmayr T., Albrecht B., Bartholdi D., Beygo J., Di Donato N., et al. Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: an exome sequencing study. Lancet 2012, 380:1674-1682.
47. Raychaudhuri S., Korn J.M., McCarroll S.A., Altshuler D., Sklar P., Purcell S., Daly M.J. Accurately assessing the risk of schizophrenia conferred by rare copy-number variation affecting genes with brain function. PLoS Genet. 2010, 6:e1001097. International Schizophrenia Consortium.
48. Rees E., Walters J.T., Chambert K.D., O'Dushlaine C., Szatkiewicz J., Richards A.L., Georgieva L., Mahoney-Davies G., Legge S.E., Moran J.L., et al. CNV analysis in a large schizophrenia sample implicates deletions at 16p12.1 and SLC1A1 and duplications at 1p36.33 and CGNL1. Hum. Mol. Genet. 2014, 23:1669-1676. Wellcome Trust Case Control Consortium.
49. Rees E., Walters J.T., Georgieva L., Isles A.R., Chambert K.D., Richards A.L., Mahoney-Davies G., Legge S.E., Moran J.L., McCarroll S.A., et al. Analysis of copy number variations at 15 schizophrenia-associated loci. Br. J. Psychiatry 2014, 204:108-114.
50. Roberts E. Prospects for research on schizophrenia. An hypotheses suggesting that there is a defect in the GABA system in schizophrenia. Neurosci. Res. Program Bull. 1972, 10:468-482.
51. Rodrigues S.M., Schafe G.E., LeDoux J.E. Intra-amygdala blockade of the NR2B subunit of the NMDA receptor disrupts the acquisition but not the expression of fear conditioning. J. Neurosci. 2001, 21:6889-6896.
52. Sanders S.J., Murtha M.T., Gupta A.R., Murdoch J.D., Raubeson M.J., Willsey A.J., Ercan-Sencicek A.G., DiLullo N.M., Parikshak N.N., Stein J.L., et al. De novo mutations revealed by whole-exome sequencing are strongly associated with autism. Nature 2012, 485:237-241.
53. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014, 511:421-427. Schizophrenia Working Group of the Psychiatric Genomics Consortium.
54. Shapira S.K., McCaskill C., Northrup H., Spikes A.S., Elder F.F., Sutton V.R., Korenberg J.R., Greenberg F., Shaffer L.G. Chromosome 1p36 deletions: the clinical phenotype and molecular characterization of a common newly delineated syndrome. Am. J. Hum. Genet. 1997, 61:642-650.
55. Stephan K.E., Friston K.J., Frith C.D. Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring. Schizophr. Bull. 2009, 35:509-527.
56. Sullivan P.F., Daly M.J., O'Donovan M. Genetic architectures of psychiatric disorders: the emerging picture and its implications. Nat. Rev. Genet. 2012, 13:537-551.
57. Szatkiewicz J.P., O'Dushlaine C., Chen G., Chambert K., Moran J.L., Neale B.M., Fromer M., Ruderfer D., Akterin S., Bergen S.E., et al. Copy number variation in schizophrenia in Sweden. Mol. Psychiatry 2014, 19:762-773.
58. Uhlhaas P.J., Singer W. Abnormal neural oscillations and synchrony in schizophrenia. Nat. Rev. Neurosci. 2010, 11:100-113.
59. Walsh T., McClellan J.M., McCarthy S.E., Addington A.M., Pierce S.B., Cooper G.M., Nord A.S., Kusenda M., Malhotra D., Bhandari A., et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 2008, 320:539-543.
60. Wang K., Li M., Hadley D., Liu R., Glessner J., Grant S.F., Hakonarson H., Bucan M. PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome Res. 2007, 17:1665-1674.
61. Williams N.M., Zaharieva I., Martin A., Langley K., Mantripragada K., Fossdal R., Stefansson H., Stefansson K., Magnusson P., Gudmundsson O.O., et al. Rare chromosomal deletions and duplications in attention-deficit hyperactivity disorder: a genome-wide analysis. Lancet 2010, 376:1401-1408.
62. Windpassinger C., Kroisel P.M., Wagner K., Petek E. The human gamma-aminobutyric acid A receptor delta (GABRD) gene: molecular characterisation and tissue-specific expression. Gene 2002, 292:25-31.
63. Xu B., Roos J.L., Levy S., van Rensburg E.J., Gogos J.A., Karayiorgou M. Strong association of de novo copy number mutations with sporadic schizophrenia. Nat. Genet. 2008, 40:880-885.
64. Xu B., Ionita-Laza I., Roos J.L., Boone B., Woodrick S., Sun Y., Levy S., Gogos J.A., Karayiorgou M. De novo gene mutations highlight patterns of genetic and neural complexity in schizophrenia. Nat. Genet. 2012, 44:1365-1369.
65. Yizhar O., Fenno L.E., Prigge M., Schneider F., Davidson T.J., O'Shea D.J., Sohal V.S., Goshen I., Finkelstein J., Paz J.T., et al. Neocortical excitation/inhibition balance in information processing and social dysfunction. Nature 2011, 477:171-178.